This Article Full Text Full Text (PDF) All Versions of this Article: 53/5/767    most recent HYPERTENSIONAHA.108.127357v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Stewart, J. M. Articles by Medow, M. S. Search for Related Content PubMed PubMed Citation Articles by Stewart, J. M. Articles by Medow, M. S. Pubmed/NCBI databases Gene GEO Profiles HomoloGene Protein UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB LOSARTAN POTASSIUM Related Collections ACE/Angiotension receptors Other Vascular biology

(Hypertension. 2009;53:767.)
© 2009 American Heart Association, Inc.

Original Articles

Defects in Cutaneous Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7) Production in Postural Tachycardia Syndrome

Julian M. Stewart; Anthony J. Ocon; Debbie Clarke; Indu Taneja; Marvin S. Medow

From the New York Medical College, Valhalla, NY.

Correspondence to Julian M. Stewart, MD, PhD, Professor of Pediatrics and Physiology, The Center for Pediatric Hypotension, Suite 1600 S, 19 Bradhurst Ave, New York Medical College, Hawthorne, NY 10532. E-mail stewart{at}nymc.edu

Postural tachycardia syndrome (POTS) is associated with increased plasma angiotensin II (Ang II). Ang II administered in the presence of NO synthase inhibition with nitro-L-arginine (NLA) and Ang II type 1 receptor blockade with losartan produces vasodilation during local heating in controls. We tested whether this angiotensin-mediated vasodilation occurs in POTS and whether it is related to angiotensin-converting enzyme 2 (ACE2) and Ang-(1-7). We used local cutaneous heating to 42°C and laser Doppler Flowmetry to assess NO-dependent conductance at 4 calf sites in 12 low-flow POTS and in 12 control subjects 17.6 to 25.5 years of age. We perfused Ringer’s solution through intradermal microdialysis catheters and performed local heating. We perfused one catheter with NLA (10 mmol/L)+losartan (2 µg/L) and repeated heating, and NLA+losartan+Ang II (10 µmol/L), repeating heating a third time. A second catheter received NLA+losartan+Ang II, heated, perfused NLA+losartan+Ang II+DX600 (1 mmol/L; a selective ACE2 inhibitor), and reheated. A third catheter received NLA+losartan+Ang II, heated, perfused NLA+losartan+Ang II+Ang-(1-7) (100 µmol/L), and reheated. The fourth catheter received Ang-(1-7) then reheated a second time only. Angiotensin-mediated vasodilation was present in control but not POTS. Ang-mediated dilation was eliminated by DX600, indicating an ACE2-related effect. Ang-mediated vasodilation was restored in POTS by Ang-(1-7). When administered alone during locally mediated heating, Ang-(1-7) improved the NO-dependent local heating response. ACE2 effects are blunted in low-flow POTS and restored by the ACE2 product Ang-(1-7). Data imply impaired catabolism of Ang II through the ACE2 pathway. Vasoconstriction in POTS may result from a reduction in Ang-(1-7) and an increase in Ang II.

Key Words: angiotensin • lasers • autonomic nervous system